Both heat and new chemotherapeutic drug dioxadet in hyperthermic intraperitoneal chemoperfusion improved survival in rat ovarian cancer model

Abstract

During HIPEC both the heat and the cytotoxic drug had antitumor effects in a rat ovarian cancer model. Dioxadet showed potential as a drug for regional chemotherapy. J. Surg. Oncol. 2016;113:438-442. © 2015 Wiley Periodicals, Inc.

Clinical efficacy and prognostic factors of CT-guided 125I brachytherapy for the palliative treatment of retroperitoneal metastatic lymph nodes

“…Since the location of the retroperitoneal lymph nodes is deep and concealed, conventional surgical resection is difficult [5,6]. It is difficult to maintain high concentrations of chemotherapies in the pelvic and abdominal lymph nodes, and systemic chemotherapy has little or no treatment effect [7][8][9][10]. Peritoneal hyperthermic perfusion has been used to concentrate drugs locally, and this can augment the antitumor response in retroperitoneal metastatic lymph nodes [11].…”

Comparative efficacy evaluation of catheter intraperitoneal chemotherapy, normothermic and hyperthermic chemoperfusion in a rat model of ascitic ovarian cancer

“…Phase II clinical trial of dioxadet has demonstrated its pronounced antitumor efficacy during IV þ IP administration with dose-limiting but reversible myelosuppression in women with advanced EOCs [11]. Its ability to penetrate tumour tissue on direct contact as well as cellcycle independent activity leads to a renewed interest of dioxadet as a compound for IP regimes [11][12][13][14].…”

Does Hyperthermic Intraperitoneal Perfusion Affect the Outcome After Cytoreductive Surgery?

“…However, the patient 7 died on day 3 after the cytoreductive surgery because of the bleeding and hemorrhagic shock. (up to 54%) and mortality (up to 11%) [1,[4][5][6]8]. The most common post-operative complications are anastomotic leakage, gastrointestinal and pancreatic fistulas, pneumonia, thromboembolism, and abdominal abscess [14].…”

“…For example, even 20 years ago patients with pseudomyxoma peritonei were suggested only interval debulking to improve their quality of life but without a chance for a long-term survival [1]. Suggesting radical peritonectomy aimed at removing as much macroscopic disease as possible followed by HIPEC to eliminate microscopic and residual disease resulted in significant improvement of outcomes with 5-and 10-years survival being 40−87 and 50% to 74% respectively [2][3][4][5][6][7][8][9][10]. However, combination cytoreductive surgery + HIPEC are considered as a treatment modality with high rate of postoperative morbidity and mortality by some authors [11].…”

“…However, combination cytoreductive surgery + HIPEC are considered as a treatment modality with high rate of postoperative morbidity and mortality by some authors [11]. Moreover, there is a consistent opinion that cytoreductive surgery alone is a safer option and adding HIPEC increases the risk of severe complications [4,6]. This hasn't been proved in any clinical study but it often makes surgeons to refuse from performing HIPEC in those patients who could benefit from this treatment.…”